- Home
- DMB vs TIL Comparison
DMB vs TIL Comparison
Compare DMB & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMB
- TIL
- Stock Information
- Founded
- DMB 2013
- TIL 2018
- Country
- DMB United States
- TIL United States
- Employees
- DMB N/A
- TIL N/A
- Industry
- DMB Trusts Except Educational Religious and Charitable
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DMB Finance
- TIL Health Care
- Exchange
- DMB Nasdaq
- TIL Nasdaq
- Market Cap
- DMB 196.9M
- TIL 177.1M
- IPO Year
- DMB N/A
- TIL 2021
- Fundamental
- Price
- DMB $10.55
- TIL $12.28
- Analyst Decision
- DMB
- TIL Strong Buy
- Analyst Count
- DMB 0
- TIL 5
- Target Price
- DMB N/A
- TIL $100.67
- AVG Volume (30 Days)
- DMB 76.6K
- TIL 72.4K
- Earning Date
- DMB 01-01-0001
- TIL 11-13-2025
- Dividend Yield
- DMB 4.17%
- TIL N/A
- EPS Growth
- DMB N/A
- TIL N/A
- EPS
- DMB N/A
- TIL N/A
- Revenue
- DMB N/A
- TIL N/A
- Revenue This Year
- DMB N/A
- TIL N/A
- Revenue Next Year
- DMB N/A
- TIL N/A
- P/E Ratio
- DMB N/A
- TIL N/A
- Revenue Growth
- DMB N/A
- TIL N/A
- 52 Week Low
- DMB $8.94
- TIL $10.80
- 52 Week High
- DMB $11.79
- TIL $42.79
- Technical
- Relative Strength Index (RSI)
- DMB 38.57
- TIL 35.84
- Support Level
- DMB $10.73
- TIL $13.53
- Resistance Level
- DMB $10.61
- TIL $13.50
- Average True Range (ATR)
- DMB 0.10
- TIL 1.36
- MACD
- DMB -0.04
- TIL -0.09
- Stochastic Oscillator
- DMB 12.50
- TIL 16.46
About DMB BNY Mellon Municipal Bond Infrastructure Fund Inc.
BNY Mellon Municipal Bond Infrastructure Fund, Inc. is a diversified closed-end management investment company. The fund's investment objective is to provide as high a current income exempt from regular federal income tax as is consistent with the preservation of capital. It invests in transportation, energy and utilities, social infrastructure, and water and environmental sectors.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.